In addition to molecular testing, there is evolving interest for anti-SARS-CoV-2 antibodies serologic assays. Majority of them focus on IgM/IgG despite IgA important role in mucosal immunity.

A simultaneous anti-SARS-CoV-2 IgA/IgG/IgM immunoassay, performed on an automated instrument by ELISA kit coated with native inactivated SARS-CoV-2, was detected on two control groups (negative swab healthcare workers; pre-pandemic healthy or with other viral infections individuals) and on two COVID-19 patient groups (early and late infection).

Specificities were 100% in all groups, indicating no cross-reactivity with other infectious or pre-pandemic sera. Sensitivities were 94% in early infection group and 97% in total positive patient group, reaching 100% in late infection group.

To our knowledge, this is the first technique based on native SARS-CoV-2. It is able to identify more positive samples than kits using recombinant antigens, therefore virus native epitopes as well as simultaneous anti-SARS-CoV-2 IgA/IgM/IgG detection could help to contain COVID-19 spreading.

除了分子检测外，人们对抗 SARS-CoV-2 抗体血清学检测的兴趣也在不断增加。尽管 IgA 在粘膜免疫中起重要作用，但他们中的大多数人都关注 IgM/IgG。

在两个对照组（阴性拭子医护人员；大流行前健康或与其他病毒感染个体）和两个 COVID-19 患者组（早期和晚期感染）。

所有组的特异性均为 100%，表明与其他感染性或大流行前血清没有交叉反应。早期感染组的敏感性为94%，总阳性患者组为97%，晚期感染组达到100%。

据我们所知，这是第一种基于原生 SARS-CoV-2 的技术。与使用重组抗原的试剂盒相比，它能够识别出更多的阳性样本，因此病毒天然表位以及同时进行的抗 SARS-CoV-2 IgA/IgM/IgG 检测可能有助于遏制 COVID-19 的传播。